Feedback

Induction and Adjuvant Therapy for Operable Non-Small Cell Lung Cancer

Chi-Fu Jeffrey Yang, Shivani Shah, Tommi D’Amico
Induction and Adjuvant Therapy for Operable Non-Small Cell Lung Cancer is a topic covered in the Pearson's General Thoracic.

To view the entire topic, please or .

STS Cardiothoracic Surgery E-Book from The Society of Thoracic Surgeons provides expert guidance for Cardiac and Thoracic Surgery. Sections include Pearson’s General Thoracic, Esphageal, Adult Cardiac, and Pediatric and Congenital Cardiac Surgery. Explore these free sample topics:

-- The first section of this topic is shown below --

Key Points

  • Chemotherapy given prior to surgery has been shown to improve survival in both early-stage and locally advanced non-small-cell lung cancer (NSCLC), although typically induction chemotherapy is recommended for only locally advanced NSCLC
  • There are no significant differences in survival between patients undergoing induction chemotherapy and induction chemoradiation for N2 NSCLC
  • Chemotherapy given after surgery for N1 and N2 NSCLC has been shown to improve survival. Adjuvant chemotherapy should also be considered for patients with stage IB disease with high-risk factorsT
  • Adjuvant radiation is not currently recommended for early-stage NSCLC that has been completely resected. Adjuvant radiation may be considered in select cases of stage IIIA after discussion in a multidisciplinary setting. Radiation can be considered after surgery for R1 and R2 resection
  • Several new randomized trials are evaluating the efficacy of molecularly targeted agents and immunotherapy in the induction and adjuvant setting

-- To view the remaining sections of this topic, please or --

Key Points

  • Chemotherapy given prior to surgery has been shown to improve survival in both early-stage and locally advanced non-small-cell lung cancer (NSCLC), although typically induction chemotherapy is recommended for only locally advanced NSCLC
  • There are no significant differences in survival between patients undergoing induction chemotherapy and induction chemoradiation for N2 NSCLC
  • Chemotherapy given after surgery for N1 and N2 NSCLC has been shown to improve survival. Adjuvant chemotherapy should also be considered for patients with stage IB disease with high-risk factorsT
  • Adjuvant radiation is not currently recommended for early-stage NSCLC that has been completely resected. Adjuvant radiation may be considered in select cases of stage IIIA after discussion in a multidisciplinary setting. Radiation can be considered after surgery for R1 and R2 resection
  • Several new randomized trials are evaluating the efficacy of molecularly targeted agents and immunotherapy in the induction and adjuvant setting

There's more to see -- the rest of this entry is available only to subscribers.

Last updated: January 3, 2020